BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 17974156)

  • 1. Cyclin dependent kinase inhibitor p27(kip1) expression and subcellular localization in relation to cell proliferation in hepatocellualr carcinoma.
    Shehata MA; Nosseir HR; Nagy HM; Farouk G
    Egypt J Immunol; 2006; 13(1):115-30. PubMed ID: 17974156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GADD45-alpha expression in cirrhosis and hepatocellular carcinoma: relationship with DNA repair and proliferation.
    Gramantieri L; Chieco P; Giovannini C; Lacchini M; Treré D; Grazi GL; Venturi A; Bolondi L
    Hum Pathol; 2005 Nov; 36(11):1154-62. PubMed ID: 16260267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival.
    Nakai S; Masaki T; Shiratori Y; Ohgi T; Morishita A; Kurokohchi K; Watanabe S; Kuriyama S
    Int J Oncol; 2002 Apr; 20(4):769-75. PubMed ID: 11894123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance.
    Claudio PP; Russo G; Kumar CA; Minimo C; Farina A; Tutton S; Nuzzo G; Giuliante F; Angeloni G; Maria V; Vecchio FM; Campli CD; Giordano A
    Clin Cancer Res; 2004 May; 10(10):3509-17. PubMed ID: 15161709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis.
    Qin LF; Ng IO
    Hum Pathol; 2001 Aug; 32(8):778-84. PubMed ID: 11521219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27(Kip1).
    Zhao Y; Tang Q; Ni R; Huang X; Wang Y; Lu C; Shen A; Wang Y; Li C; Yuan Q; Chen H; Cheng C; He S
    Hum Pathol; 2013 Mar; 44(3):365-73. PubMed ID: 22995332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse expression of Jun activation domain binding protein 1 and cell cycle inhibitor p27Kip1: influence on proliferation in hepatocellular carcinoma.
    Berg JP; Zhou Q; Breuhahn K; Schirmacher P; Patil MA; Chen X; Schäfer N; Höller TT; Fischer HP; Büttner R; Gütgemann I
    Hum Pathol; 2007 Nov; 38(11):1621-7. PubMed ID: 17651785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
    Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Hastazeris K; Salmas M; Stefanaki S; Agnantis NJ
    Urol Int; 2004; 73(1):65-73. PubMed ID: 15263796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma.
    Jing Z; Nan KJ; Hu ML
    World J Gastroenterol; 2005 Apr; 11(13):1910-6. PubMed ID: 15800979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27Kip1 in hepatocellular carcinoma.
    Nan KJ; Jing Z; Gong L
    World J Gastroenterol; 2004 May; 10(10):1425-30. PubMed ID: 15133847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferating cell nuclear antigen (PCNA) activity in hepatocellular carcinoma, benign peri-neoplastic and normal liver.
    Mun KS; Cheah PL; Baharudin NB; Looi LM
    Malays J Pathol; 2006 Dec; 28(2):73-7. PubMed ID: 18376794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of cyclins in hepatocellular carcinoma and its correlation to tumor cell apoptosis].
    Peng SH; Yang JF; Xie PP; Deng H; Li H; Feng DY
    Ai Zheng; 2005 Jun; 24(6):695-8. PubMed ID: 15946481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
    Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
    J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the G1-S modulators in hepatitis B virus-related hepatocellular carcinoma and dysplastic nodule: association of cyclin D1 and p53 proteins with the progression of hepatocellular carcinoma.
    Choi YL; Park SH; Jang JJ; Park CK
    J Korean Med Sci; 2001 Aug; 16(4):424-32. PubMed ID: 11511787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of p16 contributes to p27 sequestration by cyclin D(1)-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma.
    Matsuda Y; Ichida T; Genda T; Yamagiwa S; Aoyagi Y; Asakura H
    Clin Cancer Res; 2003 Aug; 9(9):3389-96. PubMed ID: 12960127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.
    Ito Y; Matsuura N; Sakon M; Miyoshi E; Noda K; Takeda T; Umeshita K; Nagano H; Nakamori S; Dono K; Tsujimoto M; Nakahara M; Nakao K; Taniguchi N; Monden M
    Hepatology; 1999 Jul; 30(1):90-9. PubMed ID: 10385644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma.
    Fiorentino M; Altimari A; D'Errico A; Cukor B; Barozzi C; Loda M; Grigioni WF
    Clin Cancer Res; 2000 Oct; 6(10):3966-72. PubMed ID: 11051245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CKS1B overexpression implicates clinical aggressiveness of hepatocellular carcinomas but not p27(Kip1) protein turnover: an independent prognosticator with potential p27 (Kip1)-independent oncogenic attributes?
    Huang CW; Lin CY; Huang HY; Liu HW; Chen YJ; Shih DF; Chen HY; Juan CC; Ker CG; Huang CY; Li CF; Shiue YL
    Ann Surg Oncol; 2010 Mar; 17(3):907-22. PubMed ID: 19866239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients.
    Hsieh YH; Su IJ; Yen CJ; Tsai TF; Tsai HW; Tsai HN; Huang YJ; Chen YY; Ai YL; Kao LY; Hsieh WC; Wu HC; Huang W
    Carcinogenesis; 2013 Feb; 34(2):475-85. PubMed ID: 23172669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells.
    Motomura W; Takahashi N; Nagamine M; Sawamukai M; Tanno S; Kohgo Y; Okumura T
    Int J Cancer; 2004 Jan; 108(1):41-6. PubMed ID: 14618613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.